capella

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:

• Guideline recommendations for selecting a new ART regimen
• Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
• Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV

Presenter:

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

To download the slides:
https://bit.ly/3OcqxIE

To view the full online program:
https://bit.ly/3ZjSFhg

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:

• Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimens
• Maintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABC
• ART regimen simplification
• When to perform genotypic resistance testing, including for PWH who have been off ART
• When to perform DNA genotyping for archived resistance testing
• Considering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ART
• Using boosted DRV + DTG in salvage regimens
• Switching from boosted PIs to INSTIs in PWH receiving second-line therapy
• Second-line regimens with LA CAB + RPV failure 

Christine Katlama, MD 
Professor 
Sorbonne University APHP Paris 
Head, HIV/Hepatitis Clinical and Research Unit 
Department of Infectious Diseases 
Paris, France 

Babafemi Taiwo, MBBS 
Gene Stollerman Professor of Medicine 
Chief, Division of Infectious Diseases 
Northwestern University Feinberg School of Medicine 
Chicago, Illinois 

Link to full program: https://bit.ly/3Z44Gq3

In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:

• Efficacy data
• Initiation strategies
• Virologic failure data
• Safety information

Presenter:

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

To download the slides:
http://bit.ly/3Jb1ofX

To view the full online program:
https://bit.ly/3ZjSFhg

In this episode,  Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, including

• Prevention strategies
• LA therapies
• Investigational agents

Presenters:

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University 
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME/CE program supported by an independent educational grant from Gilead Sciences, Inc.; 
Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare. 

Link to full program:
https://bit.ly/3iFEF0T

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: 

• Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
• Risk factors for virologic failure of LA CAB + RPV
• The ATLAS-2M study
• Combined clinical trials of LA CAB + RPV
• Practical considerations for LA CAB + RPV
• Implementation of LA CAB + RPV 
• Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
• Supporting candidates for LA antiretroviral therapy (ART)
• Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
• Future LA ART 
• The investigational LA HIV capsid inhibitor lenacapavir (LEN)
• LEN resistance from the CAPELLA and CALIBRATE studies
• LEN injection-site reactions in the CAPELLA and CALIBRATE studies

Presenter: 

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides at:
http://bit.ly/3Gh9AKG

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

• Prevention strategies
• Oral therapies
• LA therapies
• Cure
• COVID-19 in PWH

Faculty
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Follow along with the slides at
bit.ly/3SLuhBq

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: 

• Prevention
  • Cabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studies
  • Novel PrEP therapies in development, including islatravir and lenacapavir
• Initial therapy
  • Lenacapavir for initial therapy with results from the CALIBRATE study
• Switch strategies
  • Cabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancy
• Heavily treatment–experienced patients
  • Currently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumab
  • Lenacapavir for heavily treatment–experienced patients with results from the CAPELLA study

Presenters:

Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy 

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3vWhjHj

Link to full program:
https://bit.ly/3fOl0XX

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

• Prevention strategies
• LA therapies
• Second-line therapies
• The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
• The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
• Comorbidities and cure
• ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
• IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z

Link to full program:
https://bit.ly/3tSpdAx

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:

• A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
• The scope of the problem, including data from the CNICS cohort
• DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
• Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
• Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA

Presenters:

W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

Josep M. Llibre, MD, PhD
S­enior Consultant Physician and Clinical Researcher
Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Badalona
Barcelona, Spain  

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at: 
https://bit.ly/3z9AtL0

Link to full program:
https://bit.ly/2TXTYWx

Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV.

Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies. 

Learn how to:

• Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies and managing treatment-experienced patients with HIV
• Integrate individual patient factors such as drug–drug interactions, comorbidities, pregnancy status, adherence, and dosing preferences when selecting optimal ART
• Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens in individualized care

Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Jean-Michel Molina, MD, PhD
Head of the Department of
Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Professor of Infectious Diseases
University of Paris
Paris, France

Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics 
University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy

Follow along with the slides at: 
https://bit.ly/329c8ZP

See the entire program at:
https://bit.ly/3FkRofM

In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:

• First-line therapies
  • BIC/FTC/TAF in a test-and-treat model in IMEA 055 FAST
  • Week 144 data of ISL + DOR in treatment-naive patients from P011
• Switch Strategies
  • Data on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS Cohort
• Long-Acting Therapies
  • Efficacy and safety of LA CAB + RPV by BMI
  • Long-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trials
  • Patient satisfaction with LA CAB + RPV from the CARISEL study
  • Resistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patients
• COVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWH

Presenter:

Tristan J. Barber, MA, MD, FRCP
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/32RCX4N

Link to full program:
https://bit.ly/3G2GknK

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  

This episode includes discussion of:

• An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124
• A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWH
• CALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWH
• A Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patients
• A Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEP
• ZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TB

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.  

This episode includes discussion of:

• A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19
• A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimens
• A Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimen

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:

• The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
• The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
• An extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patients
• The CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic setting
• The HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender women
• The CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectively

In addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.

Presenters:

Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
San Francisco, California

Jason Schafer, PharmD
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Content based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.

Link to full program:
https://bit.ly/3z8SBnC

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:

• WHO Global Clinical Platform: COVID-19 outcomes in PWH
• 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
• Investigational antiretroviral use
  • CAB LA + RPV LA in treatment-naive PWH (FLAIR)
• Investigational antiretroviral agents
  • LEN (CAPELLA, CALIBRATE)
  • ISL (P011, P016)
• Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)

Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at: 
https://bit.ly/3syWD5T

Link to full program: 
https://bit.ly/3z8SBnC

You are cordially invited to a special dinner party where we have a little experiment to see what would happen when you bring together a group of international people for a special meal and book reading at the inaugural ‘La Cena’. Our guests represent a modern diverse Scotland and come from Brazil, Ireland, France, Italy and Scotland and we thank them all for their participation. 

Italy and Love are synonymous so what better way to spend the most romantic day of the year when our host Eleonora Vanello (Instagram @ele_foodfairy) from Italy beautifully reads, in English, extracts from the ‘Food of Love’ by Anthony Capella. 

The story recalls Laura Patterson, an American exchange student in Rome who, fed up with being inexpertly groped by her young Italian beaus, decides there's only one sure-fire way to find a sensual man: date a chef. Then she meets Tomasso, who's handsome, young -- and cooks in the exclusive Templi restaurant. Perfect. Except, unbeknownst to Laura, Tomasso is in fact only a waiter at Templi -- it's his shy friend Bruno who is the chef.

Recreating recipes from the ‘Food of Love’ Sabrina Damiani (Instagram @sabrinadamiani) artistically reproduces a menu to whet the appetite and initiate conversation amongst our guests.

Listen into the conversations around the table from what is expected of men in the 21st Century, the latest netflix movie from Taylor Swift to ideas for the next dinner.

Remember to follow us on Instagram @NibbleScotland and we would love to hear your reviews and feedback. Please don't forget to subscribe so you don't miss a future episode and should you wish to take part or feature in a future episode please contact us on junecarroll@mac.com 

In this episode Zach and Eric discuss all of the NBA trades this year and who were the winners and losers. A fun episode to keep you updated on who went where and how it affects the playoff race.

Elyse Segebart is an artist by nature but took the plunge into tech at 27. She's a mobile application developer finishing her degree at Capella University where she is studying software development, is graduating September of 2020. She aspires to work fully remote in the future. She lives in the heartland with her boyfriend and is a role model for his 8-year-old daughter. 

Content Warning

Elyse advocates for women in traumatic and abusive situations having overcome these situations herself. Our conversation today covers topics on addiction, domestic abuse, and issues of mental health. She brings her whole self to our conversation and shares both encouragement and advice to those facing abuse and trauma. She speaks of how she overcame the obstacles that stood in her way and encourages those who similarly hope to follow their dreams of succeeding in the tech industry. She wants to help other women who have been in similar situations to know that there is a way out. She is your cheerleader and champion and this episode is genuinely not one to miss! 

Resources:  

Mom’s in Tech Slack group

CodeNewbie podcast 

Getting Apps Done podcast

Follow Elyse on Twitter @elyseis12

We Belong Here Podcast: 

Follow Lauren on Twitter @LoLoCoding 

WeBelongPodcast.com website

Subscribe on Apple Podcasts 

Subscribe on Spotify 

LoLoCoding.com 

Jordan Raynor sits down with Horst Schulze, Co-founder of The Ritz Carlton Hotel Company, to talk about the world’s best hotels, how he thinks about loving every employee as himself, and why Christians ought to have the highest standards of excellence in our work.

Links Mentioned

• Excellence Wins
• Horst Schulze
• Capella Hotel Group
• Ritz-Carlton Hotel
• The Huka Lodge
• Master of One
• Ken Blanchard
• Threshold 360
• Tim Keller
• Dan Cathy
• Stephen Covey
• Jordan Raynor